Shu-Qun Cheng

TL;DR: It is suggested that HBV infection and activity of the TGF-β-miR-34a-CCL22 axis serve as potent etiological factors to predispose HCC patients for the development of PVTT, possibly through the creation of an immune-subversive microenvironment to favor colonization of disseminated HCC cells in the portal venous system.

TL;DR: The new guidelines were endorsed and promulgated by the Bureau of Medical Administration of the National Health Commission of the People’s Republic of China in December 2019 and reflect the real-world situation in China regarding diagnosing and treating liver cancer in recent years.

TL;DR: The results suggest that serum miR-122 might serve as a novel and potential noninvasive biomarker for detection of HCC in healthy subjects, moreover, it might serveAs a novel biomarkers for liver injury but not specifically for Detection of H CC in chronic HBV infection patients.

TL;DR: Liver resection is justified in selected patients with PVTT located in the segmental or sectoral branches of the portal vein, however, surgical resection for PVTT involving the portal bifurcation or the main trunk is still controversial.

TL;DR: Although it might not affect the HCC-promoting potential of Ct-HBx, NA treatment is effective in normalizing liver function, decreasing HBV-HCC recurrence, and improving postoperative survival.